

Advances in EGFR Inhibitor Biomarkers

Sunday, August 2, 2009 | 7:00-8:00 AM | 2nd Floor – 2001, 2003, and 2005 | San Francisco, CA

Speakers **Paul A. Bunn Jr, MD**

James Dudley Chair in Cancer Research
Professor and Director
University of Colorado Cancer Center

Frances A. Shepherd, MD, FRCP

Scott Taylor Chair in Cancer Research
Professor of Medicine, University of Toronto
Division of Medical Oncology, Princess Margaret Hospital



Sponsored by **biodesix**

This presentation was selected by the 13th World Conference on Lung Cancer Programme Committee as an independent educational activity held in conjunction with the **13th World Conference on Lung Cancer**. This presentation is not sponsored or endorsed by the IASLC.

Advances in EGFR Inhibitor Biomarkers

Biodesix is a fully integrated molecular diagnostic company that is realizing the potential of personalized medicine by enabling physicians to improve patient outcomes through mass spectrometry (MS)-based molecular profiling. Biodesix uses its proprietary ProTS® Platform to rapidly discover and validate diagnostic tests. Biodesix' first commercial product, VeriStrat®, is now available for physicians to help guide their treatment of patients with non-small cell lung cancer (NSCLC).

Location **Sunday, August 2, 2009**

7:00-8:00 AM – Breakfast will be provided during the symposium

Moscone West 2001, 2003, and 2005 – 2nd Floor

The Moscone Center | 747 Howard Street | San Francisco, CA

Speakers **Paul A. Bunn Jr, MD**

James Dudley Chair in Cancer Research
Professor and Director
University of Colorado Cancer Center

Dr. Bunn's research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews, and 90 book chapters on lung cancer. Dr. Bunn's studies have set standards for the treatment of lung cancer, identified issues of natural history, and identified biomarkers of prognosis and therapy selection. Dr. Bunn is the Principal Investigator for numerous national and local therapeutic trials and is also the Principal Investigator for the SPORE grant in lung cancer, which is designed to conduct translational research.

Frances A. Shepherd, MD, FRCP

Scott Taylor Chair in Cancer Research
Professor of Medicine, University of Toronto
Division of Medical Oncology, Princess Margaret Hospital

Dr. Shepherd is an award-winning researcher, professor, and senior staff physician at Princess Margaret Hospital, University Health Network in Toronto, where she holds the Scott Taylor Chair in Lung Cancer Research. As Chair, Dr. Shepherd plays a vital role in attracting graduate students, scientists, other doctors, and further research funding, which will enable her team to intensify their study of lung cancer. Dr. Shepherd has been the Co-Investigator or Principal Investigator for more than 100 trials, many of which have changed treatment for early-stage and advanced-stage patients with lung cancer around the globe. Dr. Shepherd sits on numerous national and international lung cancer advisory boards and chairs and/or sits on several data and safety monitoring boards for international lung cancer trials in Europe and North America. She has authored more than 330 peer-reviewed publications and 35 book chapters.